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A B S T R A C T
Purpose
To study the outcome of histologic transformation (HT) in a large prospective cohort of patients with
follicular lymphoma (FL) who previously responded to immunochemotherapy.
Patients and Methods
After a median 6-year follow-up of 1,018 randomly assigned patients from the PRIMA trial, disease
progression was observed in 463 patients, 194 of whom had histologic documentation.
Results
Forty patients had histology consistent with HT, and 154 had untransformed FL (median time to re-
currence, 9.6 v 22.8 months, respectively; P = .018). Thirty-seven percent of biopsies performed during
the ﬁrst year of follow-up showed HT corresponding to 58% of all HTs. Altered performance status,
anemia, high lactate dehydrogenase level, “B” symptoms, histologic grade 3a, and high Follicular
Lymphoma International Prognostic Index scores at diagnosis were identiﬁed as HT risk factors. Re-
sponse (complete v partial) to immunochemotherapy or rituximabmaintenance had no impact on the risk
of HT. After salvage treatment, patients with HT had less frequent complete response (50.3% v 67.4%;
P = .03) and more disease progression (28.2% v 9.6%; P , .001) than patients without HT. Estimated
overall survival for the patientswith HTwas poorer (median, 3.8 v 6.4 years; hazard ratio, 3.9; 95%CI, 2.2
to 6.9). Autologous stem cell transplantation improved the outcomes of patients with HT (median overall
survival, not reached v 1.7 years) but not of patients with persistent FL histology.
Conclusion
HT in patients with FL who previously responded to immunochemotherapy is an early event as-
sociated with a poor outcome that may deserve intensive salvage with autologous stem cell
transplantation. These data emphasize the necessity for biopsy at the ﬁrst recurrence of FL.
J Clin Oncol 34:2575-2582. © 2016 by American Society of Clinical Oncology
INTRODUCTION
Follicular lymphoma (FL) is the most common
indolent form of non-Hodgkin lymphoma, and
it is characterized by heterogeneous clinical
evolution. Histologic transformation (HT) is the
culmination of a series of biologic events leading
to aggressive lymphoma; it is histologically de-
ﬁned by the documentation of increased num-
bers of large cells that eliminate the follicular
structure, the most frequent manifestation being
diffuse large B-cell lymphoma (DLBCL).1 If HT
is suspected because of the presence of several
clinical characteristics, then histologic docu-
mentation2 remains the gold standard for di-
agnosis. The overall rate of transformation
reported in patients with FL ranges from 16%
to 60%, depending on the number of serial
biopsies and the duration of follow-up in the
different historical series.3-8 Annual incidence has
been estimated at approximately 3% in various
reports.8-10 Previously associated with a poor
prognosis,8-10 this dismal outcome may be im-
proved by the introduction of rituximab.11 Re-
cent retrospective and registry studies have
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suggested that the risk of HT might be slightly lower in the
rituximab era, and median overall survival (OS) has also
improved.12-15 However, these retrospective reports include
heterogeneous populations of symptomatic and asymptom-
atic patients who received a variety of ﬁrst-line treatment
strategies.
The PRIMA (Primary Rituximab and Maintenance) trial
was a randomized phase III trial that evaluated the impact of
maintenance with rituximab in symptomatic patients with FL
who were treated with an induction regimen of rituximab
chemotherapy. After a median follow-up of more than 6 years,
the maintenance strategy with rituximab signiﬁcantly improved
progression-free survival (PFS) but not OS.16 The objectives of
this analysis were to evaluate the incidence of HT at ﬁrst re-
currence in the PRIMA patient cohort, to study the risk factors
(at diagnosis) associated with this event, and to assess the
outcomes of these patients.
PATIENTS AND METHODS
PRIMAwas a prospective phase III trial that included patients with high
tumor burden FL by the Groupe d’Etude des Lymphomes Folliculaires
criteria17 recruited between 2004 and 2007. Patients with histologic
grades 1, 2, or 3a FL, according to the WHO classiﬁcation, were in-
cluded. Diagnostic biopsies were centrally reviewed. Patients received
six cycles of rituximab plus cyclophosphamide, doxorubicin, vincris-
tine, and prednisone and two additional doses of rituximab (n = 885
patients), or eight cycles of rituximab plus cyclophosphamide, vin-
cristine, and prednisone (n = 272 patients), or six cycles of rituximab
plus ﬂudarabine, cyclophosphamide, and mitoxantrone (n = 45 pa-
tients). At the end of induction, patients with responsive disease (complete
response [CR] or partial response [PR]) were randomly allocated to 2 years
of maintenance with rituximab (every 2 months) or observation. A total
of 1,018 patients were randomly assigned: 513 in the observation arm
and 505 in the rituximab maintenance arm. One patient was excluded
from the analysis after a histologic review of the initial diagnostic
material showed DLBCL. This study included the 1,017 randomly
assigned patients in CR or PR after the induction regimen. The rate of
HT at recurrence was originally deﬁned as a secondary end point of the
study protocol, with HT deﬁned (according to WHO criteria) as pro-
gression to high-grade lymphoma (namely, DLBCL or Burkitt lym-
phoma) with more large cells associated with loss of the follicular
structure.
The cumulative incidence of HTwas evaluated and compared with
the cumulative incidence of recurrences with conﬁrmed ongoing FL
histology. The time to ﬁrst recurrence with FL or HTwas deﬁned as the
time from the date of random assignment to the date of ﬁrst recurrence
with FL histology or HT. To assess the pretreatment risk factors for
transformation, the initial characteristics of patients with biopsies
that showed HT were compared with those of patients without HT
(ie, corresponding to the patients with biopsies that showed persistent
FL histology and those without disease progression [CONSORT dia-
gram; Fig 1]). In further exploratory analyses, the clinical outcomes of
patients with HTwere then evaluated and compared with the outcomes
of patients who had a recurrence and conserved FL histology. The OS
from random assignment was calculated from the date of random
assignment to the date of death related to any cause or to the date of last
follow-up for patients still alive. The OS from the ﬁrst recurrence was
calculated from the time of ﬁrst recurrence or HT to the date of death
related to any cause or to the date of last follow-up for the patients still
alive. Statistical analyses were performed with SAS v9.2 software (SAS
Institute, Cary, NC).
RESULTS
Incidence of HT
After a median follow-up of 73 months, a total of 463
patients experienced disease recurrence or progression (45.5%
of the randomly assigned patients); 194 of these patients (42%)
underwent biopsy at ﬁrst progression. Data regarding the de-
cision to perform a biopsy or not and its site are unavailable. The
patients with and without biopsies had comparable initial
clinical characteristics, except for less frequent anemia (19.7% in
the biopsy group v 29.9% in the nonbiopsy group; P = .011;
Appendix Table A1, online only). Among the 194 biopsies per-
formed, 40 had HT (20.6%), and 154 had FL histology. During
the ﬁrst year, 66 of 144 relapsing patients had a biopsy: 42 (63.6%)
showed FL and 24 (36.4%) showedHT. More than half (58%) of the
total documented cases of HT occurred within the ﬁrst year of
follow-up, with a median time of 9.7 months from random
assignment. This timing was signiﬁcantly shorter than the time
to progression for patients with FL histology documentation
(median, 22.9 months; log-rank test P = .017). At 6 years after
induction, the cumulative incidence of documented HTwas 4.1%
versus 15.9% for the incidence of documented progression with FL
histology. These results do not consider the group of patients who
did not have a biopsy. The distribution of the cumulative in-
cidence over time seemed to differ between the patients with
documented FL histology recurrence and HT (Appendix Figure
A1, online only). It increased sharply for HT during the ﬁrst year
after induction treatment (58% of all cases of documented HT),
whereas it increased linearly for FL histology relapses over the
ﬁrst 6 years. Indeed, 36.4% of the biopsies performed during
the ﬁrst year after random assignment demonstrated HT com-
pared with 11.8% of the biopsies performed after 1 to 5 years of
follow-up.
At ﬁrst recurrence, patients with HT more frequently man-
ifested a new site of disease involvement (80%; 32 of 40) compared
with the patients with FL histology (60.4%; 93 of 154; P = .02).
Patients randomly
assigned
(N = 1,018)
Histologic review: DLBCL (n = 1)
No relapse
(n = 554)
Relapse
(n = 463)
No biopsy
(n = 269; 58%)
Biopsy
(n = 194; 42%)
Follicular lymphoma
histology
(n = 154; 79.4%)
Histologic
transformation
(n = 40; 20.6%)
Fig 1. CONSORT diagram. DLBCL, diffuse large B-cell lymphoma.
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They also more frequently had extranodal disease (55% [22 of 40]
v 45% [69 of 154]; P = .2), although this was not statistically
signiﬁcant.
Risks Factors for HT
The initial clinical characteristics of the 40 patients with HT
were compared with those of the 708 patients without HT (154
with persistent FL histology at ﬁrst recurrence and 554 without
recurrence). As shown in Table 1, the patients with HT more
frequently had a histologic grade of 3a, an Eastern Cooperative
Oncology Group (ECOG) performance status (PS) $ 2, a hemo-
globin level , 12 g/dL, a lactate dehydrogenase (LDH) level above
the upper limit of normal, the presence of “B” symptoms, and
a Follicular Lymphoma International Prognostic Index (FLIPI)
score . 2 at study entry (pretreatment) compared with the other
patients. In a multivariate analysis that included parameters with
a P value , .2, only an ECOG PS $ 2 and hemoglobin , 12 g/dL
Table 1. Initial Clinical and Biological Characteristics at the Time of FL Diagnosis Among Patients With and Without HT in the PRIMA Trial
Characteristic
Patients With Available Data
P
No Transformation
(n = 708)*
HT
(n = 40)
No. % No. %
Age, years .84
Range 23-81 33-77
Mean 56 56.5
Median 57 57
Sex .19
Female 358 50.6 16 40
Male 350 49.4 24 60
FL grade .02
1 304 43 8 20
2 255 36 19 47
3 148 21 13 33
ECOG performance status , .001
0-1 689 97.3 34 85
2-4 19 2.7 6 15
B symptoms .042
Yes 211 29.8 18 45
No 497 70.2 22 55
No. of extranodal sites .33
Range 0-7 0-6
Mean 1.4 1.6
Median 1 1
No. of nodal sites .29
Range 0-9 1-9
Mean 5 5.4
Median 5 6
. 4 370 52.3 23 57.5 .518
Bulky disease .27
Yes 330 47.4 22 56.4
No 366 52.6 17 43.6
Ann Arbor stage .11
I-II 81 11.4 1 2.5
III-IV 627 88.6 39 97.5
Anemia, g/dL , .001
, 12 127 17.9 16 40
$ 12 581 82.1 24 60
LDH .029
# ULN 488 69 21 52.5
. ULN 219 31 19 47
FLIPI score .007
0-1 176 24.9 3 7.5
2 252 35.6 12 30
3-5 279 39.5 25 62.5
Albumin, g/L .105
, 35 48 8.4 6 18.2
$ 35 524 91.6 27 81.8
B2 microglobulin, mg/L .605
, 3 481 72.9 25 69.4
$ 3 179 27.1 11 30.6
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma; FLIPI, Follicular Lymphoma International Prognostic Index; HT, histologic
transformation; LDH, lactate dehydrogenase; ULN, upper limit of normal.
*The 708 patients without HT corresponded to the 554 patients without relapse and the 154 patients with recurrence and biopsy showing FL histology.
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were independently associated with HT: hazard ratio (HR) of 5.6
(95% CI, 1.7 to 17.7) for ECOG PS and HR of 3.7 (95% CI, 1.4 to
9.7) for anemia. With the limitation of modest patient num-
bers, the induction regimen (rituximab plus cyclophospha-
mide, doxorubicin, vincristine, and prednisone, rituximab plus
cyclophosphamide, vincristine, and prednisone, or rituximab plus
ﬂudarabine, cyclophosphamide, and mitoxantrone) did not seem
to inﬂuence the risk of transformation (data not shown). Among
the 708 patients without HT, 382 (54%) had received rituximab
maintenance, and among the 40 patients with HT, only 16 (40%)
had received rituximab maintenance. In addition, the quality of the
response to the induction regimen was comparable between the
two groups: 42.5% of patients with HT had CR, 30% had
unconﬁrmed CR (CRu), and 27.5% had PR compared with
42.2%, 31.6%, and 25.3%, respectively, for patients without HT
(P = .98).
Outcomes of Patients With HT
To analyze the outcomes of the patients with HT, we com-
pared their outcomes with those of patients with FL histology at
recurrence. Among the patients with a biopsy showing FL, 135
(87.7%) received therapy after the ﬁrst recurrence, whereas among
the patients with HT, 39 (97.5%) underwent treatment. The
treatments used (Table 2) included chemotherapy and anti-CD20
immunotherapy for the majority of the patients with HT who
underwent DLBCL-like intensive regimens. The patients with FL
histology received various treatments, including radiation alone,
rituximab alone, and rituximab chemotherapy. Patients with HT
were less likely to achieve CR or CRu (50.3% v 67.4%; P = .03;
Table 3) and more patients frequently had progressive disease
under salvage therapy (28.2% v 9.6%; P, .001) than those with FL
histology. They also had shorter survival from recurrence than the
154 patients with FL histology (median OS, 3.8 v 6.4 years; HR, 3.9;
95% CI, 2.2 to 6.9; P , .001; Fig 2). This was also true when
considering only those patients with disease progression within
12 months of immunochemotherapy (P = .007). After salvage
therapy, among the 40 patients with HT, 17 (42%) underwent
consolidation with high-dose chemotherapy and autologous stem
cell transplantation (ASCT). These 17 patients had an improved
OS rate (not reached [NR] v 1.7 years; Fig 3A) compared with the
23 who could not reach ASCT or were not referred to ASCT.
Among the patients with FL histology at recurrence, 44 (28%)
underwent salvage therapy followed by ASCT. ASCT had no impact on
OS (Fig 3B) of the relapsing patients with FL histology. To limit bias, we
performed the same analysis by excluding patients who had an early
progression after salvage (with a 6-month landmark analysis) and who
were older than age 65 years—an age potentially considered the limit for
transplantation eligibility. Results were similar: ASCT had no impact on
OS in the population of patients relapsing with FL (medianOS, 6.4 years
[95% CI, 4.7 to 6.4 years] vNR [95% CI, NR to NR] for the 42 and 59
patients who were treated with or without ASCT, respectively), whereas
patients with HTand age younger than 65 years who received an ASCT
(n= 16) had a longerOS than those who did not (n= 9;medianOS,NR
[95% CI, 3.8 to NR] v 1.7 years [95% CI, 0.5 to NR]). Among the 40
patients with HTat recurrence, 16 received rituximabmaintenance after
induction treatment. This prolonged rituximab exposure did not seem
to have an adverse impact on their response to salvage treatment or their
outcomes (median OS for the 16 patients was 4.9 years [95% CI, 1.4 to
6.5 years] vNR [95% CI, 3.4 years to NR]; P = .159, for the 24 patients
who did not receive maintenance).
Finally, the OS rate of the 269 patients who did not undergo
biopsy at recurrence was slightly higher than that for the 194
patients who underwent biopsy, although the difference was not
signiﬁcant (median OS, NR v 6.4 years for the group of patients
without and with biopsy, respectively; HR, 1.46; 95% CI, 0.99 to
2.22; P = .056; Appendix Figure A2, online only).
DISCUSSION
This study reports on the incidence, risk factors, and outcomes of
patients with HT of high tumor burden FL who responded to
a rituximab chemotherapy regimen. The originality of this report is
represented by the inclusion of well-characterized patients who
were homogenously treated and followed in a prospective clinical
trial, whereas other reports have included patients with various
Table 2. Salvage Type Therapy at Recurrence, According to Biopsy Results
Type of Therapy
Treated Patients
With FL Histology
(n = 135)
With HT
(n = 39)
No. % No. %
Chemotherapy 113 83.7 37 95
Radiotherapy 14 10.4 8 20.5
Immunotherapy 116 85.9 28 71.8
Radioimmunotherapy 13 9.6 0
ASCT 44 32.6 17 43.6
Allotransplant 2 1
NOTE. Among the patients with a biopsy showing follicular lymphoma (FL), 135
(87.7%) were treated after the ﬁrst recurrence, 112 (83%) of whomwere treated
immediately after the recurrence. Among the patients with histologic trans-
formation (HT), 39 (97.5%) received treatment, 35 (89.7%) of whom received
treatment immediately after the documentation of HT (four patients received
treatment between 3 and 12 months after the HT documentation, and one
patient did not receive any treatment). The principal immunochemotherapy
regimen was rituximab plus dexamethasone, cytarabine, and oxaliplatin
(R-DHAOX) for patients with FL and those with HT; other regimens included
rituximab plus bendamustine or rituximab plus ﬂudarabine and cyclophospha-
mide (R-FC) for relapsing patients with FL histology; less commonly used
regimens consisted of rituximab plus etoposide, cytarabine, steroid, and plati-
num (R-ESHAP) or rituximab plus etoposide, ifosfamide, and carboplatin (R-ICE)
for patients with HT. ASCT, autologous stem-cell transplantation.
Table 3. Response to Salvage Therapy, According to Biopsy Results
Type of Response
FL Histology
(n = 135)
HT
(n = 39)
No. % No. %
CR/CRu 91 67.4 20 50.3
PR 19 14.1 5 12.8
Stable 7 5.2 2 5.1
Progressive 13 9.6 11 28.2
Not evaluated 5 3.7 1 2.6
NOTE. Nineteen patients in the follicular lymphoma (FL) group and one patient
in the histologic transformation (HT) group did not undergo salvage treatment.
Abbreviations: CR, complete response; CRu, unconﬁrmed CR; PR, partial
response.
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initial management strategies. Furthermore, only the ﬁrst disease
progression event was considered in this study as opposed to other
studies that have reported on late HT events after multiple disease
relapses.
In this study, HT at ﬁrst progression remained a relatively
uncommon event that typically occurred soon after the end of
induction treatment, whereas the risk of progression with FL
histology seemed to be linear over time (up to 6 years of follow-
up). Interestingly, more than half of the transformations were
documented during the ﬁrst year after induction, which represents
a third of the biopsies performed during that period versus 11.8%
being documented during the next 4 years. The recurrence kinetic
strengthens the importance of performing a biopsy for any relapse
within the ﬁrst year of follow-up. Link et al13 reported that HT
incidence seemed to diminish after 5 years of follow-up and that it
was consistent throughout 1 to 5 years, with an overall incidence of
10.7% at 5 years, which is similar to our results. This different
temporal pattern might be at least partially explained by the in-
clusion of different populations: asymptomatic patients with FL at
diagnosis were included in the US study by Link et al,13 whereas our
study only considered the HT occurring in patients with high
tumor burden and who had responded to initial immunoche-
motherapy. The median time to transformation was also shorter in
our study (ie, 9 months from the end of induction) than in studies
that included symptomatic and asymptomatic patients with FL at
diagnosis (40 and 33 months, respectively10,12).
A current challenge in managing patients with FL is to identify
(at the time of diagnosis) those at high risk of treatment failure and
poor outcomes.18 This group of patients may include those with
a higher risk of HT, which emphasizes the need to identify the risk
factors for transformation. Despite the recent progress made in
deciphering the molecular features of HT,19-21 clinical features
remain the only routinely available method for identifying risk
factors. In our population, ECOG PS, anemia, high LDH level,
presence of B symptoms, high FLIPI score, and histologic grade 3a
at diagnosis were associated with a higher incidence of HT at
recurrence. ECOG PS and anemia were the only independent
factors in multivariate analysis. Before the rituximab era, advanced
Ann Arbor stage, low serum albumin level (, 35 g/L), high b2-
microglobulin (. 3 mg/L), and a high FLIPI score at diagnosis
appeared to be risk factors for HT.8-10 In more recent reports,
increased LDH, ECOG PS . 1, B symptoms, more than one
extranodal site, and FLIPI score at diagnosis were associated with
the risk of HT.12-14 It would be interesting to further merge large
clinical series obtained in the rituximab era to deﬁne a score that
might identify these patients at risk for HT at diagnosis. In ad-
dition, for patients who demonstrate clinical risk factors for HTat
the time of their initial diagnosis, it may be helpful to track occult
transformation, perhaps even repeating a biopsy (eventually guided
with positron emission tomography-computed tomography scans)
to optimize initial management.
The inﬂuences of initial patient management and the response
to the induction regimen on risk of transformation have also been
debated. It remains unclear whether patients who are initially
managed with watchful waiting have a higher risk of HT.9,13,14,17,22
In the PRIMA trial and in reports of other studies,13,14 no dif-
ference in HT was observed according to the different induction
regimen used, whereas one study10 suggested that there is a di-
minished risk in patients treated with an anthracycline. Older
reports have suggested that failure to achieve CR was associated
with a higher risk of transformation.8 In this report, the quality of
response (CR v PR) did not have a signiﬁcant impact on the in-
cidence of transformation. Finally, rituximabmaintenance reduced
the overall risk of lymphoma progression and therefore the number
of patients with HT (P = .08). But given the limited number of pa-
tients with HT, the sample size does not allow us to establish whether
rituximab maintenance had an impact on the risk of HT among
patients with disease progression.
The patients with HT had a poorer OS rate than the relapsing
patients with FL histology. Among the patients with HT, the
median OS rate from ﬁrst relapse was 3.8 years compared with
more than 6 years for the patients with FL histology, which
1 2 3 4 5 6 7
Time From First Occurrence (years)
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154 141 116 89 62 24 5 0
No. at risk
Persistent FL
histology
HT histology 40 29 21 15 12 9 0
+ Censored
Log-rank P < .001
HT histology
Persistent FL histology
Fig 2. Overall survival (OS) of 194 patients
with documentation of histologic trans-
formation (HT) or persistent follicular lym-
phoma (FL) after ﬁrst recurrence in the
PRIMA trial, according to transformation
status. Patients with HT histology had
a shorter median OS (n = 40; median, 3.8
years; 95% CI, 1.7 years to not reached [NR])
than patients with FL histology (n = 154;
median, 6.4 years; 95% CI, NR to NR; hazard
ratio, 3.9; 95% CI, 2.2 to 6.9; P , .001).
Among patients who progressed within
12 months, those with HT histology had
a shorter OS (n = 23; median, 2 years; 95%
CI, 0.8 years to NR) than those with FL
histology (n = 41; median, 6.4 years; 95%
CI, 4.7 to 6.4 years; P = .007).
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strengthens the necessity of performing a biopsy at the ﬁrst re-
currence of FL. Importantly, prolonged treatment with rituximab
(ie, maintenance after induction regimen) did not have an impact
on the OS of the HT patients after relapse. The OS after HTappears
to be comparable to that in other reports from the rituximab
era13,14,23 (5-year OS, 48% to 50%), thereby conﬁrming the im-
provement achieved in the rituximab era. However, this outcome
appears to be inferior to that observed for newly diagnosed pa-
tients with DLBCL. The median OS rate after relapse in this study
(3.6 years) seems to be similar to the OS rate of relapsed patients
with DLBCLwho are eligible for transplantation, as reported in the
CORAL (Collaborative Trial in Relapsed Aggressive Lymphoma)
study (median OS, approximately 4 years).24
As shown here, when achievable, ASCT seems to improve the
outcomes of HT patients; however, this result was not observed in
patients with persistent FL histology at progression. The efﬁcacy of
ASCT has also been reported in other studies25-29 but not in the
recent US study by Link et al.13 Only patients who responded and
were adequately ﬁt were eligible for ASCT, which biases the in-
terpretation of these data and the potential beneﬁt of ASCT. When
reported, the transplantation rate among initial eligible patients
was approximately 50% to 60%.30-33 A retrospective comparison of
young patients who did not undergo ASCT for a reason other than
progression still shows good results, with an OS rate comparable to
or slightly inferior to that of grafted patients.23,30
Our study has some limitations. We analyzed only those
patients who were randomly assigned in the PRIMA trial after
responding to induction therapy. The study population was
therefore selected, thus limiting wider applicability of the ﬁndings.
For instance, among the 86 patients who did not respond to in-
duction therapy, 31 had a biopsy: 23 biopsies showed FL and eight
(26%) showed HT. These patients were not followed as per
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B
Fig 3. Overall survival (OS) of patients with
a ﬁrst recurrence according to histology (his-
tologic transformation [HT] (A) versus follicular
lymphoma [FL] (B) at ﬁrst recurrence) and
according to treatment with or without autol-
ogous stem cell transplantation (ASCT) after
salvage therapy. OS was calculated from ﬁrst
recurrence. (A) Among the 40 patients with HT,
17 had an ASCT and an improved OS estimate
(median, not reached [NR]; 95% CI, 3.8 years
to NR) compared with the 23 who could not
reach ASCT or were not referred for ASCT
(median, 1.7 years; 95% CI, 0.6 to 3 years). (B)
Among the 154 patients with FL histology at
recurrence, 44 (28%) had an ASCT. ASCT had
no impact on the OS estimate of relapsing
patients with FL histology. Median OS was 6.4
years (95% CI, 4.7 to 6.4 years) for those who
received an ASCT and was not reached for
those who did not receive an ASCT.
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protocol and therefore are not reported here. Given the multi-
centric nature of the study, a central review of biopsies performed
at ﬁrst recurrence was not possible, but all individual patient
medical records and pathologic reports were carefully reviewed.
When estimating the risk factors for HT, the patients who did not
undergo new biopsies were not considered, but this population
likely includes patients with and without transformation, and their
exclusion avoids further confounding factors.
In conclusion, this report of HT among a cohort of high-
tumor burden patients with FL who were treated with immu-
nochemotherapy shows that HT is a relatively uncommon event
that remains associated with a poor prognosis. The cumulative
incidence was signiﬁcant within the ﬁrst year and then diminished
compared with the incidence of FL relapse, which continuously
increased. Management after the ﬁrst progression indicates that
there may be a beneﬁt from ASCT for patients with HT, whereas
this strategy was not associated with a better OS rate for patients
with persistent FL histology at ﬁrst progression. Our results further
emphasize the need to perform a new biopsy at the time of ﬁrst
progression in patients with FL. Although intensive treatment may
represent a good option for younger patients and those who are
eligible for ASCT, the remaining population still represents a group
of patients with an unmet medical need.
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Appendix
Table A1. Comparison of Initial Clinical and Biological Characteristics of Patients With a First Recurrence in the PRIMA Trial Who Had a Histologic Documentation
(biopsy) and Those Who Did Not.
Characteristic
No Histologic Documentation
(n 5 269), No. (%)
Histologic Documentation
(n 5 194), No. (%) Test
Age, years Wilcoxon P 5 .8
Mean (SD) 55.8 (11.58) 55.7 (12.60)
Median 57.0 57.0
Sex x2 P 5 .5
Female 111 (41.3) 86 (44.3)
Male 158 (58.7) 108 (55.7)
Initial pathology diagnosis
FL grade 1 117 (43.5) 72 (37.1)
FL grade 2 89 (33.1) 78 (40.2)
FL grade 3 3 (1.1) 1 (0.5)
FL grade 3A 28 (10.4) 16 (8.2)
NA 32 27
ECOG performance status x2 P 5 .4
0 172 (63.9) 115 (59.3)
1 86 (32.0) 67 (34.5)
2 11 (4.1) 12 (6.2)
3 0 (0.0) 0 (0.0)
4 0 (0.0) 0 (0.0)
Extranodal sites Wilcoxon P 5 .8
N 269 194
Mean (SD) 1.7 (1.33) 1.8 (1.39)
Median 2.0 2.0
Nodal area Wilcoxon P 5 .2
No. 269 194
Mean (SD) 6.0 (2.68) 5.8 (2.49)
Median 7.0 6.0
Hemoglobin, g/dL x2 P 5 .011
, 12 53 (19.7) 58 (29.9)
$ 12 216 (80.3) 136 (70.1)
Albumin, g/L x2 P 5 .4
, 35 18 (8.3) 17 (10.4)
$ 35 200 (91.7) 147 (89.6)
NA 51 30
Abbreviations: ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma; NA, not available; SD, standard deviation.
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Fig A1. Cumulative incidence of a documented histological transformation or persistent follicular lymphoma (FL) at ﬁrst recurrence in the PRIMA trial, among patients in
the maintenance intent-to-treat population who experienced disease progression.
1.0
0.8
0.6
0.4
0.2
0
1941 170 137 104 74 33 5 0
2692 230 197 154 108 47 8 0
1 2 3
Time From First Recurrence (years)
Ov
er
al
l
Su
rv
iv
al
 (p
ro
ba
bi
lit
y)
4 5 6 7
No. of Subjects Event Censored Median Survival (95% CI)
194 24.7 % (48) 75.3 % (146) 6.4 (NA ; NA)Biopsy
269 17.1 % (46) 82.9 % (223) Not reachedNo biopsy
2: No biopsy
1: Biopsy
+ Censored
Log-rank P = .0560
Fig A2. Overall survival from random assignment of patients with a ﬁrst recurrence in the PRIMA trial and according to the existence of biopsy at relapse.
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